-
[Editor's note: This story discusses off-label use of the antidepressant medication escitalopram (Lexapro, Forest Laboratories, New York City).]
-
You have just reviewed instructions on proper oral contraceptive (OC) use with your patient, a 22-year-old mother of three.
-
When the Ortho Evra transdermal contraceptive (Ortho Women's Health & Urology, Raritan, NJ) was introduced in 2002, use of the patch caught on quickly with young women.
-
-
Recent investigation into the molecular pathogenesis of epithelial ovarian cancer has implicated two dominant phenotypes.
-
After two pretreatment cycles, 196 patients with menorrhagia were randomized to tranexamic acid or placebo.
-
A ruptured ectopic pregnancy is the leading cause of maternal mortality in the first trimester and accounts for 10 to 15% of all maternal deaths.
-
What is your facility's policy on providing multiple pill packs? Results of a new study might make you rethink your strategy.
-
Since its introduction in 2009, use of the non-latex FC2 Female Condom (Women's Health Co., Chicago) has grown.
-
An ED program designed to serve the terminally ill? It makes perfect sense to Mark Rosenberg, DO, MBA, FACEP, chairman of emergency medicine at St. Joseph's Regional Medical Center in Paterson, NJ. So much so, in fact, that his department recently introduced Life-Sustaining Management and Alternative (LSMA) services. The program is designed to provide comfort, control, and choices for chronic and terminally ill patients and their loved ones.